Macquarie Group’s Regulus Therapeutics RGLS Stock Holding History

Macquarie Group’s Portfolio RGLS Stock Details RGLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-865	Closed	-$2	–	2085
2024 Q1	$2	Buy	+865	New	+$1.41K	﹤0.01%	1856
2018 Q3	–	Sell	-167	Closed	-$13K	–	2247
2018 Q2	$13K	Hold	167	–	–	﹤0.01%	2111
2018 Q1	$14K	Hold	167	–	–	﹤0.01%	2108
2017 Q4	$21K	Hold	167	–	–	﹤0.01%	2208
2017 Q3	$25K	Hold	167	–	–	﹤0.01%	2073
2017 Q2	$20K	Hold	167	–	–	﹤0.01%	1498
2017 Q1	$33K	Hold	167	–	–	﹤0.01%	1514
2016 Q4	$45K	Sell	167 -250	-60%	-$81.3K	﹤0.01%	1505
2016 Q3	$165K	Hold	417	–	–	﹤0.01%	1435
2016 Q2	$145K	Hold	417	–	–	﹤0.01%	1442
2016 Q1	$347K	Hold	417	–	–	﹤0.01%	1289
2015 Q4	$436K	Hold	417	–	–	﹤0.01%	1198
2015 Q3	$327K	Sell	417 -503	-55%	-$516K	﹤0.01%	1331
2015 Q2	$1.21M	Buy	920 +223	+32%	+$360K	﹤0.01%	1139
2015 Q1	$1.42M	Buy	+697	New	+$1.51M	﹤0.01%	1085

Other funds holding RGLS

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Macquarie Group's RGLS Position: Q2 2024 in Review

Macquarie Group sold out of Regulus Therapeutics (RGLS) in Q2 2024, closing a stake of 865 shares — an estimated $2 sold.

Macquarie Group first reported a position in RGLS in Q1 2015 and held it in 15 quarters. The position peaked at $1.42M in Q1 2015. 63 funds tracked by Wall St. Rank hold RGLS as of Q2 2024.

Macquarie Group reported no remaining Regulus Therapeutics position as of Q2 2024 after selling out during the quarter.
Macquarie Group sold 865 Regulus Therapeutics shares in Q2 2024, an estimated $2.
Macquarie Group first reported a position in Regulus Therapeutics in Q1 2015 and held it in 15 quarters.
Macquarie Group's Regulus Therapeutics position peaked at $1.42M in Q1 2015.
63 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.